India vs U.S.A: Pharma Tariffs, Russian Oil Penalty & Trade Deal Breakdown | Full Analysis
.jpg)
Trump's Triple Play: India Reeling from 100% Pharma Tariff, Russian Oil Sanctions, and Trade Deal Collapse A perfect storm of U.S. sanctions—100% pharma tariffs, a 50% Russian oil penalty, and a trade deal collapse—has left India's economic resilience on trial. What’s really going on? As U.S.-India relations navigate choppy waters under the Trump administration, three interconnected economic pressures are reshaping bilateral ties. These include steep tariffs on pharmaceutical imports, punitive duties tied to energy sourcing, and protracted negotiations over a comprehensive trade agreement. Backed by recent developments, market analyses, and expert insights, this article dissects each challenge, drawing from official announcements and data to reveal the broader implications for India's economy, global trade, and investment landscape. Segment 1: Breakdown of Pharma Tariffs—Who’s Affected and Who’s Exempt The U.S. pharmaceutical market, valued at over $600 bill...